A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prostate-specific antigen level (no greater than 10 ng/mL vs greater than 10 but no greater than 20 ng/mL vs greater than 20 ng/mL), tumor stage (T1b-2 vs T3-4), Gleason score (2-4 vs 5-6 vs 7-10), and prior hormonal therapy (yes vs no). Patients are randomized to one of two treatment arms.
Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 1,540 patients (770 per treatment arm) will be accrued for this study within 4 years.
Inclusion Criteria
Adenocarcinoma of prostatic origin histologically-confirmed within 180 days of the randomization date.
Zubrod Performance Status 0-1 (Appendix II).
Prostatic biopsy tumor grading by the Gleason Score classification (Appendix VI) is mandatory prior to randomization.
Patients at intermediate risk for disease relapse as determined by any of the following combinations of factors (NOTE: tumor found in one or both lobes on biopsy, but not palpable, will not alter T stage):
Clinically negative (N0) lymph nodes (LN) as established by imaging (pelvic ± abdominal CT, MRI or LAG), or negative LN by nodal sampling or dissection (laparoscopy or laparotomy). Patients with radiologic (e.g., CT, MRI or LAG) or radioimmunoscintigraphy (i.e., ProstaScint™) findings suggestive of regional nodal involvement are eligible if cytologic (e.g., needle aspiration) or histologic (e.g., surgical sampling) evaluation shows no evidence of a neoplastic process (i.e., prostatic or non-prostatic malignancy). Patients with equivocal radiologic findings (maximum nodal size ≤ 1.5 cm) are eligible.
No distant (M0) metastases. Patients with radionuclide imaging (e.g., bone scintigraphy, ProstaScint™) findings suggestive, but not diagnostic of metastatic disease are eligible if radiologic (e.g., standard or tomographic radiography, or CT/MRI) imaging does not confirm metastatic disease.
Pretherapy serum (total) prostate-specific antigen value performed with a Federal Drug Administration approved assay method, e.g. Abbott, Hybritech, etc.
Treatment must begin within 6 weeks after randomization.
Alanine aminotransferase (ALT) must be within 2 x upper normal limit.
Patients must sign a study-specific informed consent form (Appendix I) prior to randomization.
Exclusion Criteria
Patients at high risk for disease relapse as determined by either:
Patients at low risk for disease relapse as determined by:
• Clinical stage ≤T2, Gleason score ≤ 6, and prostate-specific antigen ≤ 10.
Clinical stage Tx, T0, or T1a.
Histologic or radiologic evidence of tumor involvement of regional lymph nodes (N1) or the presence of metastatic disease (M1).
Pretherapy serum prostate-specific antigen level > 100.
Co-morbid medical illness which in the opinion of the investigator is expected to result in a life expectancy of <10 years.
Any of the following prior therapies:
Previous or concomitant invasive cancer, other than localized basal cell or squamous cell skin carcinoma (AJCC Stage 0-II), unless continually disease free for at least 5 years.
Major medical or psychiatric illness which, in the opinion of the investigator, would prevent completion of treatment or would interfere with follow-up.
The patient's participation in another medical research study that involves prostate cancer treatment.
Birmingham, Alabama 35294-3300, United States
Loma Linda, California 92354, United States
Los Angeles, California 90033-0804, United States
Denver, Colorado 80010, United States
Grand Junction, Colorado 81502-1628, United States
Gainesville, Florida 32610-0385, United States
Chicago, Illinois 60611-3013, United States
Maywood, Illinois 60153, United States
Indianapolis, Indiana 46202, United States
Lexington, Kentucky 40536-0293, United States
Louisville, Kentucky 40202, United States
Louisville, Kentucky 40215, United States
Baltimore, Maryland 21201, United States
Baltimore, Maryland 21231-2410, United States
Boston, Massachusetts 02114, United States
Jamaica Plain, Massachusetts 02130, United States
Columbia, Missouri 65203, United States
Omaha, Nebraska 68114-4199, United States
Omaha, Nebraska 68198-7521, United States
Lebanon, New Hampshire 03756-0002, United States
Mount Holly, New Jersey 08060, United States
Brooklyn, New York 11203, United States
New York, New York 10032, United States
Rochester, New York 14642, United States
Syracuse, New York 13217, United States
Chapel Hill, North Carolina 27599-7295, United States
Greenville, North Carolina 27835-6028, United States
Winston-Salem, North Carolina 27157-1082, United States
Oklahoma City, Oklahoma 73104, United States
Allentown, Pennsylvania 18105, United States
Hershey, Pennsylvania 17033-0850, United States
Philadelphia, Pennsylvania 19104-4283, United States
Philadelphia, Pennsylvania 19107-5541, United States
Pittsburgh, Pennsylvania 15236, United States
Jackson, Tennessee 38301, United States
Nashville, Tennessee 37232-5671, United States
San Antonio, Texas 78284-7811, United States
Richmond, Virginia 23298-0058, United States
Seattle, Washington 98195-6043, United States
La Crosse, Wisconsin 54601, United States
St. John's, Newfoundland and Labrador A1B 3V6, Canada